好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Gender-based Differences in Parkinson’s Disease Hospitalization: A Nationwide and Single Center Study
Movement Disorders
P3 - Poster Session 3 (5:00 PM-6:00 PM)
16-004

To analyze hospital admission patterns among patients with Parkinson’s Disease (PD), comparing demographic characteristics, reasons for admission, length of stay, and discharge disposition between male and female patients.

Patients with PD have a higher risk of hospitalization compared to the general population. Understanding the factors influencing their admissions may help optimize care and resource allocation.

Data from the National Inpatient Sample (NIS) was analyzed, including 1,388,055 PD patients admitted between 2016 and 2019, identified using ICD-10 codes. Additionally, records of 211 PD patients admitted to Westchester Medical Center (WMC) between January 2023 and July 2024 were reviewed. Admission diagnoses, demographics, and discharge dispositions were compared between male and female patients. Multivariate logistic regression was conducted to examine differences in length of hospital stay, complications, and discharge disposition, adjusting for age.

Among 1,388,055 PD patients, more males (58.5%) were hospitalized than females (41.5%). The most common admission diagnoses were urinary tract infection (UTI, 4.8%), hip fracture (3.2%), pneumonia (3.2%), and deep brain stimulation (DBS) procedures with insertion of neurostimulator lead (1.1%). Females had higher rates of hip fracture, UTI, congestive heart failure, stroke, and constipation, while males were more commonly admitted for pneumonia and DBS. Among 15,090 patients admitted for DBS, 68.3% were male and 31.7% were female. At WMC, among 211 PD patients, the primary reasons for admission included falls, infections, cardiovascular conditions, behavioral disturbances, and DBS procedures. More males were admitted than females (63.98% vs. 36.02%). While no significant differences in age or discharge disposition were observed, males had a longer hospital stay than females (8.8 days vs. 6.8 days).

Males with PD were more frequently hospitalized than females, with differences in primary reasons for admission and length of hospital stay. These findings highlight the need for targeted interventions to reduce hospitalization risk and improve outcomes in PD patients.

Authors/Disclosures
Zhimin Xu, MD, PhD (Westchester Medical Center)
PRESENTER
Dr. Xu has nothing to disclose.
Nishitha Bujala, MBBS (Kamineni Institute of Medical Sciences) Dr. Bujala has nothing to disclose.
Eris Spirollari, BA Mr. Spirollari has nothing to disclose.
Andy Jiang, BS Mr. Jiang has nothing to disclose.
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College) Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .
Robert Fekete, MD Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine Biosciences, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acorda, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva Neuroscience, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acadia Pharmaceutical, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas Pharmaceutical, Inc.. Dr. Fekete has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine Biosciences, Inc.. Dr. Fekete has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal Pharmaceuticals, Inc.. Dr. Fekete has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda Therapeutics, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion, Inc.. Dr. Fekete has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink, Inc.. The institution of Dr. Fekete has received research support from Lundbeck. Dr. Fekete has received publishing royalties from a publication relating to health care. Dr. Fekete has a non-compensated relationship as a Neurological Working Group Member with Alliance for Patient Access that is relevant to AAN interests or activities.